Ocular Therapeutix, Inc.

OCUL · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.9%

Institutions95.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$51.95M	$63.72M	$58.44M	$51.49M	$43.52M	$17.40M	$4.23M	$1.99M	$1.92M	$1.89M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$6.57M	$5.63M	$5.28M	$4.54M	$4.41M	$2.08M	$2.33M	$465000	$457000	$443000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$270.02M	-$171.78M	-$82.38M	-$78.65M	-$78.04M	-$62.85M	-$85.80M	-$59.12M	-$61.92M	-$43.33M
Operating income as a percentage of revenue.	-519.8%	-269.6%	-141.0%	-152.7%	-179.3%	-361.1%	-2029.9%	-2970.8%	-3220.1%	-2296.0%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$265.94M	-$193.51M	-$80.74M	-$71.04M	-$6.55M	-$155.64M	-$86.37M	-$59.98M	-$63.39M	-$44.70M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.42	$-1.22	$-1.01	$-0.92	$-0.09	$-2.56	$-1.91	$-1.57	$-2.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-1.00	$-1.02	$-0.97	$-0.98	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$737.06M	$392.10M	$195.81M	$102.30M	$164.16M	$228.06M	$54.44M	$54.06M	$41.54M	$32.94M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$808.06M	$457.94M	$252.06M	$149.29M	$204.89M	$261.86M	$78.74M	$73.04M	$55.43M	$74.94M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	$8.29M	–	–	$5.54M	$1.55M
Everything the company owes — debt, unpaid bills, and other obligations.	$153.75M	$142.59M	$160.93M	$113.91M	$116.89M	$185.77M	$82.37M	$37.17M	$29.28M	$22.93M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$654.31M	$315.34M	$91.13M	$35.38M	$88.00M	$76.09M	-$3.63M	$35.88M	$26.15M	$52.01M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$204.88M	-$134.68M	-$70.23M	-$59.60M	-$65.55M	-$53.55M	-$77.58M	-$49.23M	-$50.47M	-$34.00M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$12.01M	$1.29M	$6.09M	$3.71M	$1.19M	$841000	$2.24M	$1.89M	$8.25M	$1.92M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$216.89M	-$135.97M	-$76.32M	-$63.32M	-$66.74M	-$54.40M	-$79.82M	-$51.12M	-$58.73M	-$35.92M

	You	Peer avg
P/E	–	25.0
Revenue Growth	+0.1%	+198.6%
ROE	-73.0%	141.5%

Ocular Therapeutix, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison